in the absence of a submission from the holder of the marketing authorisation:
avapritinib (Ayvakyt®) is not recommended for use within NHSScotland.
Indication under review: As monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice616KB (PDF)
Medicine details
- Medicine name:
- avapritinib (Ayvakyt)
- SMC ID:
- SMC2424
- Indication:
As monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.
- Pharmaceutical company
- Blueprint Medicines
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 October 2021